Institutional members access full text with Ovid®

Share this article on:

Moyamoya in a Child Treated With Interferon for Recurrent Osteosarcoma

Buchbinder, David MD, MSHS*; Steinberg, Gary MD, PhD; Linetsky, Michael MD; Casillas, Jacqueline MD, MSHS§

Journal of Pediatric Hematology/Oncology: August 2010 - Volume 32 - Issue 6 - pp 476-478
doi: 10.1097/MPH.0b013e3181e5e1db
Clinical and Laboratory Observations

Moyamoya is a cerebral vasculopathy of unknown etiology rarely described as a late effect after the treatment of childhood cancer. We describe a 12-year-old female who developed moyamoya after the completion of systemic chemotherapy, surgery, and adjuvant interferon α for osteosarcoma with pulmonary metastases. Given the importance of characterizing late effects after the treatment of childhood cancer, the potential role of interferon α in the development of moyamoya is discussed.

*Division of Hematology, Department of Pediatrics, Children's Hospital of Orange County, Main Street, Orange

Department of Neurosurgery, Stanford University School of Medicine, Pasteur Drive, Stanford

Department of Radiology

§Division of Hematology/Oncology, Department of Pediatrics, David Geffen School of Medicine at UCLA, Le Conte Avenue, Los Angeles, CA

Reprints: David Buchbinder, MD, MSHS, Division of Hematology, Department of Pediatrics, Children's Hospital of Orange County, Main Street, 455 S. Main Street, Orange (e-mail: dbuchbinder@choc.org).

Received for publication August 18, 2009; accepted April 21, 2010

© 2010 Lippincott Williams & Wilkins, Inc.